US OptionsDetailed Quotes
KRMD250117P7500
- 3.49
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open3.49Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV2.67%PremiumJan 17, 2025Expiry Date3.38Intrinsic Value100Multiplier-7DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.18Leverage Ratio--Theta--Rho--Eff Leverage--Vega
KORU Medical Systems Stock Discussion
KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter
Monday, 13th January at 8:00 am
KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, tod...
KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion
KORU Medical Systems presented data at the PODD 2024 Conference showing strong nursing preference for their FreedomEdge® Infusion System over manual syringe administration for subcutaneous oncology infusions. The stud...
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
KORU Medical Systems (NASDAQ: KRMD) announced a collaboration with a global pharmaceutical company to initiate a feasibility study for their Freedom Infusion System. This system, designed for subcutaneous administration, will be tested with an FDA and EMA approved oncology biologic drug currently administered manually by healthcare professionals. The Freedom System, ...
NEWS
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
First quarter 2024 net revenues of $8.2 million, an 11% increase YoY and record high quarterly revenues.
Core business (U.S. and International) experienced 14% growth YoY, driven by SCIg market growth, share gains, and geographic expansion.
Entered a Novel Therapies collaboration with an oncology drug therapy, bringing total collaborations to 16.
G...
judgement, prediction and technical analysis. TGIF. have a good weekend
$Rivian Automotive (RIVN.US)$
$KORU Medical Systems (KRMD.US)$
$Innoviz Technologies (INVZ.US)$
$SNDL Inc (SNDL.US)$
$Compugen (CGEN.US)$
No comment yet